Skip to Content
U.S. National Institutes of Health
Cancer Diagnosis Program Cancer Imaging Program Cancer Therapy Evaluation Program Developmental Therapeutics Program Radiation Research Program Translational Research Program Biometric Research Branch Office of Cancer Complementary and Alternative Medicine
Last Updated: 04/25/2012

CURRENT FUNDING OPPORTUNITIES

Quantitative Imaging for Evaluation of Responses to Cancer Therapies (U01)

PROGRAM ANNOUNCEMENT

PAR-11-150: http://grants.nih.gov/grants/guide/pa-files/PAR-11-150.html
(Expiration date: May 8, 2014)

Contact:
Robert Nordstrom, Ph.D.
301- 594-9121, nordstrr@mail.nih.gov

CIP is soliciting applications to promote research on quantitative imaging of tumor response to cancer therapies in clinical trial settings, with the overall goal of facilitating clinical decision making. Proposed projects should include the appropriate development and adaptation/implementation of quantitative imaging methods, protocols, and software solutions/tools (using existing commercial imaging platforms and instrumentation), and their application in current and planned phase 1/2 clinical therapy trials. No support for the clinical trials, as such, will be provided under this initiative. The proposed projects must focus on imaging-derived quantitative measurements of responses to drugs and/or radiation therapy, and/or image-guided interventions. It is anticipated that these research goals will require multidisciplinary efforts. Therefore, this announcement solicits applications from multi-disciplinary teams to include oncologists as well as clinical and basic imaging scientists. The involvement of industrial partners in the development of the quantitative imaging methods is not required, but is strongly encouraged. Awardees form a Quantitative Imaging Network (QIN) to share ideas and approaches to validate and standardize imaging data and related imaging meta-data for quantitative measurements of responses to cancer therapies.

See the CIP QIN website for a description of the program.